Tests DT402 in adults with autism spectrum disorder
Tests the drug DT402 in adults with autism spectrum disorder.
Plain-language title generated from the registry record
Registry title: A Phase 2A Trial of DT402 for Autism Spectrum Disorder
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07303907, who can take part
Where in United States
- Spectrum Neuroscience and Treatment InstituteNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Definium Therapeutics US, Inc.
- Trial code
- NCT07303907
- Record updated
- 2 September 2026
- Original description
A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum DisorderRead full original descriptionShow less
An Open-label Study Evaluating DT402 in Adults With Autism Spectrum Disorder
A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder
Inclusion: Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition); Male or Female aged 18 to 65; Presents with clinically significant deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) ≥66.
Exclusion: First degree relative with or lifetime history of a psychotic disorder or bipolar disorder; Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine); Any clinically significant unstable illness; Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking.